Phase II trial of ivacaftor in combination with lumacaftor in patients aged ≥18 years with cystic fibrosis and one copy (heterozygous) of the F508del mutation on one allele and a second mutation that is not expected to respond to either ivacaftor or lumacaftor alone.
Latest Information Update: 21 Oct 2013
At a glance
- Drugs Ivacaftor (Primary) ; Lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 21 Oct 2013 New trial record